Treatment of skin and soft-tissue infections.

Treatment of skin and soft-tissue infections.

File T M Jr; Tan J S

American journal of surgery

1995

1995-05

Bacterial infections of the skin range from mild pyodermas to life-threatening necrotizing infections. Pyodermas are most often due to Staphylococcus aureus or beta-hemolytic Streptococcus sp, whereas infections associated with skin ulcers of the extremities, infections following trauma or surgery, and histotoxic necrotizing infections may involve a large number of additional pathogens, including Enterobacteriaceae, Pseudomonas sp, enterococci, and anaerobes. Management of bacterial skin and soft-tissue infections includes appropriate surgical drainage or excision of infected tissue and antimicrobial therapy. The combination of piperacillin and the beta-lactamase inhibitor tazobactam is a newly released antimicrobial, which has excellent in vitro activity against the vast majority of pathogens involved in skin infections. Two multicenter studies recently evaluated the efficacy and safety of piperacillin/tazobactam in the therapy of skin and soft-tissue infections in hospitalized patients. Piperacillin/tazobactam was well tolerated and demonstrated high clinical efficacy for the treatment of these infections.

Humans; Necrosis; Drug Combinations; Bacterial Infections/complications/drug therapy/surgery/*therapy; beta-Lactamase Inhibitors; Fasciitis/therapy; Penicillanic Acid/analogs & derivatives/therapeutic use; Piperacillin/therapeutic use; Skin Diseases/complications/drug therapy/surgery/*therapy; Soft Tissue Infections/complications/drug therapy/surgery/*therapy; Surgical Wound Infection/microbiology; Tazobactam

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

27S–33S

5

169